% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Minicozzi:132724,
author = {P. Minicozzi and P. M. Walsh and M.-J. Sánchez and A.
Trama and K. Innos and R. Marcos-Gragera and N. Dimitrova
and L. Botta and T. B. Johannesen and S. Rossi and M. Sant
and H. Brenner$^*$},
collaboration = {E. W. Group},
title = {{I}s low survival for cancer in {E}astern {E}urope due
principally to late stage at diagnosis?},
journal = {European journal of cancer},
volume = {93},
issn = {0959-8049},
address = {Amsterdam [u.a.]},
publisher = {Elsevier},
reportid = {DKFZ-2018-00378},
pages = {127 - 137},
year = {2018},
note = {EUROCARE-5 Working Group: Collaborator from DKFZ: Brenner
H},
abstract = {Cancer survival has persistently been shown to be worse for
Eastern European and UK/Ireland patients than those of other
European regions. This is often attributed to later stage at
diagnosis. However, few stage-specific survival comparisons
are available, so it is unclear whether poorer quality
treatment or other factors also contribute. For the first
time, European cancer registries have provided
stage-at-diagnosis data to EUROCARE, enabling
population-based stage-specific survival estimates across
Europe.In this retrospective observational study, stage at
diagnosis (as TNM, condensed TNM, or Extent of Disease) was
analysed for patients (≥15 years) from 15 countries
grouped into 4 regions (Northern Europe: Norway; Central
Europe: Austria, France, Germany, Switzerland, The
Netherlands; Southern Europe: Croatia, Italy, Slovenia, and
Spain; and Eastern Europe: Bulgaria, Estonia, Lithuania,
Poland, and Slovakia), diagnosed with 7 malignant cancers in
2000-2007, and followed to end of 2008. A new variable
(reconstructed stage) was created which used all available
stage information. Age-standardised 5-year relative survival
(RS) by reconstructed stage was estimated and compared
between regions. Excess risks of cancer death in the 5 years
after diagnosis were also estimated, taking age, sex and
stage into account.Low proportions of Eastern European
patients were diagnosed with local stage cancers and high
proportions with metastatic stage cancers. Stage-specific RS
(especially for non-metastatic disease) was generally lower
for Eastern European patients. After adjusting for age, sex,
and stage, excess risks of death remained higher for Eastern
European patients than for European patients in general.Late
diagnosis alone does not explain worse cancer survival in
Eastern Europe: greater risk of cancer death together with
worse stage-specific survival suggest less effective care,
probably in part because fewer resources are allocated to
health care than in the rest of Europe. We recommend that
Eastern European cancer registries and other involved bodies
to draw attention to poor cancer survival, so as to
stimulate research and inform policies to improve outcomes.},
cin = {C070 / G110},
ddc = {610},
cid = {I:(DE-He78)C070-20160331 / I:(DE-He78)G110-20160331},
pnm = {313 - Cancer risk factors and prevention (POF3-313)},
pid = {G:(DE-HGF)POF3-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:29518726},
doi = {10.1016/j.ejca.2018.01.084},
url = {https://inrepo02.dkfz.de/record/132724},
}